Paper Review Records
All Paper Review Records
11 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Natural dehydrocostus lactone-based analogues as new structural PDPK1 allosteric activators against HBV
Hang Sun; Yu-Jing Mao; Dan-Yang Zhu; Rui-Xian Xu; Bi-Cheng Zhang; Ying Sang; Yi-Zhi Liu; Yang Feng; Guotai Yang; Hao Chen; Shao-Xing Dai; Min XuShow moreShow less
Yunnan Key Laboratory of Cross-Border Infectious Disease Control and Prevention and Novel Drug Development (Under Construction), Center for Pharmaceutical Sciences, Faculty of Life Science and Technology, Kunming University of Science and Technology, Chenggong Campus, Kunming, 650500, China; State Key Laboratory of Primate Biomedical Research, Institute of Primate Translational Medicine, Kunming University of Science and Technology, Kunming, 650500, ChinaShow moreShow less
Exploring the role of conformational restriction in 5-alkyl-6-benzyl-2-{[(methylthio)methyl]thio}pyrimidin-4(3H)-ones: Effects in HIV-1 infected cells and reverse transcriptase enzymes
Egor Degtyarenko; Gebremedhin Solomon Hailu; Emanuele Fabbrizi; Anastasia Golovina; Andrey Voronkov; Roberta Astolfi; Lidia Giuliani; Andrea Mancini; Maxim B. Nawrozkij; Vladimir Chernyshov; Clarissa Pupillo; Roberto Cirilli; Laura Bavagnoli; Rino Ragno; José A. Esté; Emmanuele Crespan; Francesco Fiorentino; Roman Ivanov; Antonello Mai; Dante RotiliShow moreShow less
Institute of Physiologically Active Compounds, Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Chernogolovka, Moscow Region, 142432, Russia; Department of Science, Roma Tre University, Rome, 00146, Italy; Department of Drug Chemistry and Technologies, Sapienza University of Rome, Rome, 00185, Italy; Medicinal Biotechnology Department, Sirius University of Science and Technology, Olimpiyskiy Ave. 1, Sirius, Krasnodar Region, 354340, Russia; Institute of Biophysics of the Future, Institutsky lane, 9, Building 7, Dolgoprudny, Moscow region, 141701, Russia; Department of Chemistry, Sapienza University of Rome, Pale Aldo Moro 5, Rome, Italy; Centro Nazionale per il Controllo e la Valutazione dei Farmaci, Istituto Superiore di Sanità, Viale Regina Elena 299, Roma, 00161, Italy; Istituto di Genetica Molecolare IGM-CNR, via Abbiategrasso 207, Pavia, 27100, Italy; Universitat Internacional de Catalunya, C/ Josep Trueta s/n., Barcelona, 08195, Spain; Department of Biochemical Sciences, Sapienza University of Rome, Rome, 00185, Italy; Biostructures and Biosystems National Institute (INBB), Rome, 00165, ItalyShow moreShow less
Targeting the myeloid immune checkpoint ILT3 (LILRB4) with small molecules enables reprogramming of suppressive tumor immunity
Somaya A. Abdel-Rahman; Antonio Monari; Tom Miclot; Florent Barbault; Moustafa T. GabrShow moreShow less
Department of Radiology, Columbia University Irving Medical Center, New York, NY, 10032, USA; Department of Radiology, Weill Cornell Medicine, New York, NY, 10065, USA; Université Paris Cité, CNRS, ITODYS, Paris, F-75013, FranceShow moreShow less
Discovery of a highly selective FLT3-ITD inhibitor with potent antileukemic activity based on 4-(2-fluorophenoxy)pyridine scaffold
Zhongyuan Wang; Yiwei Zhang; Lin Li; Yunfeng Wang; Dan Yang; Qingmei Song; Qingqing Fu; Dongsheng Zhao; Lei Tang; Weiwei Ouyang; Yue'e Chai; Weike LiaoShow moreShow less
Department of Pharmacy, Guizhou Provincial People's Hospital, Guiyang, 550002, China; State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guiyang, 550004, China; Department of Oncology, Affiliated Hospital of Guizhou Medical University and Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, 550001, China; Key Laboratory of Structure-Based Drug Design and Discovery (Shenyang Pharmaceutical University), Ministry of Education, 103 Wenhua Road, Shenhe District, Shenyang, 110016, ChinaShow moreShow less
Discovery and characterization of PGC-01: An effective GSDMD-targeting PROTAC
Qian-qian Wang; Rong-ying Hou; Yi-xuan Shua; Ya-fei Xu; Wen-jing Bian; Wen Xiao; Yu-qing Chen; Bing-yu Zhou; Yue Gao; Li Liu; Yu-hang Wang; Yi-bei Xiao; Cheng JiangShow moreShow less
School of Pharmacy, China Pharmaceutical University, 639 Longmian Avenue, Nanjing, 211198, China; Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, 210009, China; State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China; Center of Drug Metabolism and Pharmacokinetics, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, ChinaShow moreShow less
In silico identification and biological evaluation of newly synthetic hinokiflavone derivatives as multi-kinase inhibitors with preferential Aurora A activity for ovarian cancer therapy
Ke Wang; Guan-Yu Chen; Pei‐Yi Chu; Yi-Cheng Pan; Wei-Yu Hsu; Yun-Hao Dai; Yu-Liang Yang; Yeong-Jiunn Jang; Yang-Chang WuShow moreShow less
School of Pharmaceutical Sciences, Jiangsu Provincial University Key Laboratory of Green Biomanufacturing for Pharmaceuticals, Nanjing Tech University, Nanjing, 211816, China; Chinese Medicine Research and Development Center, China Medical University Hospital, Taichung, 404327, Taiwan; Master Program of Pharmaceutical Manufacture, College of Pharmacy, China Medical University, Taichung, Taiwan; Agricultural Biotechnology Research Center, Academia Sinica, Taipei, 11529, Taiwan; Graduate Institute of Integrated Medicine, College of Chinese Medicine, China Medical University, Taichung, 404333, Taiwan; Graduate Institute of Natural Products, Kaohsiung Medical University, Kaohsiung, TaiwanShow moreShow less
FAQ
How long does EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY take to review a manuscript?
As of 2026-11-19, CrushSCI has 11 complete review records for EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. The fastest paper went from submission to acceptance in 30 days (Discovery of a highly selective FLT3-ITD inhibitor with potent antileukemic activity based on 4-(2-fluorophenoxy)pyridine scaffold, received 2026-07-28, accepted 2026-08-27); the slowest took 175 days. The average is 78.1 days and the median is 60 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
